Transport proteins

Exportin 1 Drugs In Development, 2021 Research Report - ResearchAndMarkets.com

Retrieved on: 
Monday, July 19, 2021
Health, Pharmaceutical, XPO1, Transport proteins, Karyopherin, Rev, Branches of biology, Selective inhibitor of nuclear export, Nuclear pore complex

The "Exportin 1 - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exportin 1 - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Exportin 1 - Drugs In Development, 2021, outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein.
  • Furthermore, this report also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects.

Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study

Retrieved on: 
Friday, November 6, 2020
Branches of biology, Body fluids, Digestive system, Acids, Gastric acid, Transport proteins, Stomach, Proton pump

Fexuprazan is a potassium-competitive acid blocker (P-CAB), which reversibly blocks the proton pump that secretes gastric acids from the stomach wall.

Key Points: 
  • Fexuprazan is a potassium-competitive acid blocker (P-CAB), which reversibly blocks the proton pump that secretes gastric acids from the stomach wall.
  • The bridging study assessed pharmacokinetic and pharmacodynamic profiles of Fexuprazan in healthy Korean, Caucasian, and Japanese adults at the Seoul National University Hospital.
  • These study results are expected to accelerate our partnership efforts to quickly commercialize Fexuprazan in global markets, including the US and Europe."
  • The study results showed that Fexuprazan has 99% cure rate after 8 weeks of treatment and confirmed it is well-tolerate.

NTHU Unveils Ray of Hope for Improving Dementia Treatment

Retrieved on: 
Tuesday, October 6, 2020
Health, Other Health, Clinical trials, Research, Science, Biotechnology, Membrane proteins, Branches of biology, Proteins, Solute carrier family, Integral membrane proteins, Neurotransmitter transporters, Transport proteins, Ion transporter, Cotransporter

The teams research finding has been published in the August issue of Science Advances.

Key Points: 
  • The teams research finding has been published in the August issue of Science Advances.
  • Human phosphate transporter (hPiT) is an important membrane protein for transporting phosphate and sodium ions into brain cells.
  • Sun said that analyzing the human phosphate transporter and locating the site of the patients variants are important in finding a treatment for brain calcification.
  • The first step in analyzing the molecular structure of membrane protein is to cultivate the membrane protein crystal.

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism to Treat Immune-Mediated and Neurological Diseases

Retrieved on: 
Tuesday, July 21, 2020
Research, Infectious diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Transmembrane proteins, Transport proteins, Solute carrier family

The aggregate value of potential future payments to Jnana can exceed $1 billion.

Key Points: 
  • The aggregate value of potential future payments to Jnana can exceed $1 billion.
  • In addition, Jnana is continuing to develop our internal pipeline programs that target SLC transporters for diseases where patients have limited or no treatment options.
  • Jnana Therapeutics is a biotechnology company focused on modulating cellular metabolism by opening the solute carrier ( SLC ) family of metabolite transporters as a target class to develop transformational therapeutics.
  • Jnana uses its RAPID platform , a proprietary, cell-based drug discovery approach, to systematically target SLC transporters and develop best-in-class therapies to treat a wide range of diseases, including immune-mediated, neurological and metabolite-dependent diseases.

Landmark Study Reveals First Genetic Evidence of Sodium Pump's Essential Function

Retrieved on: 
Monday, June 29, 2020
Chemistry, Physical sciences, Branches of biology, Transport proteins, Caveolin, Na+/K+-ATPase, Sodium

HUNTINGTON, W.Va., June 29, 2020 /PRNewswire/ --New findings offer the first genetic evidence that the sodium pump is essential for animal organ development, according to a study led by Marshall University scientists that involves the scaffolding, or signaling, function of the sodium pump.

Key Points: 
  • HUNTINGTON, W.Va., June 29, 2020 /PRNewswire/ --New findings offer the first genetic evidence that the sodium pump is essential for animal organ development, according to a study led by Marshall University scientists that involves the scaffolding, or signaling, function of the sodium pump.
  • The research, published May 27 in Science Advances , indicates that a gene sequence in the sodium pump, also known as Na/K-ATPase, is critical to embryonic development in animals.
  • The short sequence of DNA identified in the study is nearly identical in worms, fish, chickens, birds or mammals, including humans.
  • The sequence, called the caveolin binding motif, is required for the sodium pump to be a receptor.

AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University

Retrieved on: 
Thursday, May 28, 2020
Proteins, Neurotransmitter transporters, Solute carrier family, Transport proteins, Deoxycytidine kinase, Equilibrative nucleoside transporter, Nucleoside transporter, Nucleoside analogue, DCK, Deoxycytidine, Kinase

The paper documents the results from the company's sponsored research at Wake Forest University.

Key Points: 
  • The paper documents the results from the company's sponsored research at Wake Forest University.
  • Nucleoside analogs are subject to resistance mechanisms including downregulation of equilibrative nucleoside transporter (ENT1) and deoxycytidine kinase (dCK).
  • Anthony Hayes, CEO of AIkido stated, "Wake Forest University is a world-class research facility and an outstanding partner for AIkido.
  • AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.